# EDGAR Filing Document

**Accession Number:** 0001557376
**File Stem:** 0001829126-26-006515
**Filing Date:** 2026-6
**Character Count:** 10003
**Document Hash:** a87c095234c5e0ad250856dc3525ae38
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-006515.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001829126-26-006515

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260616

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260616

**DATE AS OF CHANGE**: 20260616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeo ScientifiX, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55008
- **FILM NUMBER:** 261092894

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **DATE OF NAME CHANGE:** 20180625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 16, 2026**

**<u>ZEO SCIENTIFIX, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-55008** | **47-4180540** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3321 College Avenue, Suite 246<br> Davie, Florida** | **33314** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(888) 963-7881</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this "**Report**"), and unless otherwise indicated, the terms "**the Company**," "**ZEO**," "**we**," "**us**" and "**our**" refer to Zeo ScientifiX, Inc.

**Item 8.01 Other Events.**

On June 16, 2026, ZEO issued a press release announcing that ZEO's Medical Advisory Board member Constantino Mendieta, MD, recently participated in a humanitarian medical mission in Cusco, Peru to provide specialized reconstructive care to treat approximately 38 child patients recovering from severe burn injuries which included the use by Dr. Mendieta of products that had been donated to him by ZEO.

A copy of the press release is included as **Exhibit 99.1** to this Report.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits* 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated June 16, 2026](zeoscientifix_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: June 16, 2026 | **ZEO SCIENTIFIX, INC.** | **ZEO SCIENTIFIX, INC.** |
|  | By: | /s/ Ian T. Bothwell |
|  |  | Ian T. Bothwell<br> Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

FOR IMMEDIATE RELEASE

**ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru**

*ZEO Medical Advisory Board Member Dr. Constantino Mendieta joins humanitarian effort providing reconstructive*

*care to children recovering from severe burn injuries in Cusco, Peru*

DAVIE, FLORIDA — June 16, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX) ("ZEO ScientifiX" or the "Company"), a biologics research and products company dedicated to advancing the science and development of regenerative biologics products for therapeutic use and a leader in educating physicians on the science of regenerative medicine, announced that ZEO's Medical Advisory Board member Constantino Mendieta, MD, recently participated in a humanitarian medical mission in Cusco, Peru to provide specialized reconstructive care to treat approximately 38 child patients recovering from severe burn injuries which included the use by Dr. Mendieta of products that had been donated to him by ZEO ScientifiX.

The 10-day mission brought together reconstructive surgeons, healthcare professionals, therapists, psychologists, volunteers, and nonprofit organizations to provide care to pediatric burn survivors and their families. During the mission, approximately 80 children were evaluated, with nearly 40 reconstructive surgeries performed over six days at the Regional Hospital of Cusco.

"ZEO ScientifiX was honored to support this mission by contributing products that helped make this level of care possible for children and families who may not otherwise have access to specialized reconstructive treatment," said Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX. "This mission reflects the heart of regenerative medicine — using science, innovation, and physician expertise to improve lives in a meaningful way."

ZEO ScientifiX's product donation represents part of the Company's broader commitment to supporting physician-led care, regenerative medicine education, and initiatives that expand access to advanced therapeutic options for patients in need.

As part of the mission, Dr. Mendieta worked alongside local and international medical professionals to evaluate patients, develop surgical plans, and perform reconstructive procedures aimed at restoring function, mobility, confidence, and quality of life.

"Something that has deeply impacted me during this experience is that many of these children do not see themselves as victims," said Dr. Mendieta. "They continue to play, laugh, dream, and live with a joy that transcends any visible scar. Their spirits remain unbroken."

The mission also included support from organizations including Aniquem and Fundación Aromas, along with psychologists, therapists, volunteers, healthcare professionals, and supporters whose combined efforts helped children and families move from fear and pain toward healing and renewed confidence.

Known for his innovations in reconstructive surgery, Dr. Mendieta serves on the ZEO ScientifiX Medical Advisory Board, where he contributes to physician education and scientific initiatives focused on advancing patient care.

Physicians interested in learning more about ZEO ScientifiX's educational programs and physician partnership opportunities may contact the Company directly.

**About ZEO ScientifiX (OTCQB: ZEOX)**

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University's Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. ZEO ScientifiX supplies clinicians seeking to drive clinical excellence and sustainable practice growth through its cutting-edge biologics and regenerative therapies. For more information, visit https://zeoscientifix.com.

**Forward-Looking Statements**

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

**Media Contact**

ZEO ScientifiX, Inc.<br>Karlista Maroney<br>Director of Growth Strategy<br>ir@zeoscientifix.com